Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Panbela Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PBLA
Over the counter
8731
https://panbela.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Panbela Therapeutics Inc
Panbela Announces Poster Presentation at American Association for Cancer Research:
- Apr 18th, 2024 12:00 pm
Panbela Announces Transfer to OTCQB Market
- Apr 16th, 2024 9:29 pm
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
- Mar 26th, 2024 8:10 pm
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
- Mar 12th, 2024 8:15 pm
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
- Feb 15th, 2024 1:00 pm
Panbela Announces Closing of Approximately $9.0 Million Public Offering
- Feb 1st, 2024 12:00 pm
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
- Jan 30th, 2024 1:15 pm
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
- Jan 29th, 2024 11:15 am
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
- Jan 25th, 2024 12:00 pm
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
- Jan 18th, 2024 1:15 pm
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
- Jan 16th, 2024 1:00 pm
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
- Dec 21st, 2023 2:15 pm
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
- Dec 18th, 2023 1:15 pm
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
- Dec 4th, 2023 1:00 pm
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
- Nov 29th, 2023 1:15 pm
Panbela Provides Business Update and Reports Q3 2023 Financial Results
- Nov 9th, 2023 9:10 pm
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
- Nov 3rd, 2023 11:55 am
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
- Nov 2nd, 2023 12:15 pm
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
- Oct 31st, 2023 12:15 pm
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
- Oct 25th, 2023 12:15 pm
Scroll